Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships

2003 ◽  
Vol 74 (6) ◽  
pp. 569-580 ◽  
Author(s):  
D Soy
Keyword(s):  
Human Immunodeficiency Virus ◽  
Population Pharmacokinetics ◽  
Pediatric Patients ◽  
Exposure Response ◽  
Immunodeficiency Virus

scholarly journals STEADY-STATE PHARMACOKINETICS OF LOPINAVIR/RITONAVIR IN COMBINATION WITH EFAVIRENZ IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PEDIATRIC PATIENTS

2009 ◽  
Vol 28 (2) ◽  
pp. 159-161 ◽  
Author(s):  
Jennifer R. King ◽  
Edward P. Acosta ◽  
Ram Yogev ◽  
Andrew Wiznia ◽  
Joyce Kraimer ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Steady State ◽  
Pediatric Patients ◽  
Immunodeficiency Virus

scholarly journals Population Pharmacokinetics of Nevirapine, Zidovudine, and Didanosine in Human Immunodeficiency Virus-Infected Patients

1999 ◽  
Vol 43 (1) ◽  
pp. 121-128 ◽  
Author(s):  
Xiao-Jian Zhou ◽  
Lewis B. Sheiner ◽  
Richard T. D’Aquila ◽  
Michael D. Hughes ◽  
Martin S. Hirsch ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Body Weight ◽  
Population Pharmacokinetics ◽  
Compartment Model ◽  
Volume Of Distribution ◽  
Zero Order ◽  
Triple Combination ◽  
Entire Study ◽  
First Order ◽  
Immunodeficiency Virus

ABSTRACT The population pharmacokinetics of nevirapine (NVP), zidovudine (ZDV), and didanosine (ddI) were evaluated in a total of 175 patients infected with human immunodeficiency virus randomized to receive either a double combination of ZDV plus ddI or a triple combination of NVP plus ZDV plus ddI as a substudy of the AIDS Clinical Trials Group Protocol 241. Levels (approximating 3.5 determinations/patient) of the three drugs in plasma were measured during 44 of a total 48 weeks of study treatment, and a set of potential covariates was available for nonlinear mixed-effect modeling analysis. A one-compartment model with zero-order input and first-order elimination was fitted to the NVP data. Individual oral clearance (CL) and volume of distribution (V) averaged 0.0533 liters/h/kg of body weight and 1.17 liters/kg, respectively. Gender was the only covariate which significantly correlated with the CL of NVP. ZDV and ddI data were described by a two-compartment model with zero-order input and first-order elimination. Individual mean oral CL,V SS (volume of distribution at steady state), and V of ZDV were 1.84 liters/h/kg and 6.68 and 2.67 liters/kg, respectively, with body weight and age as correlates of CL and body weight as a correlate of V SS. The average individual oral CL, V SS, andV of ddI were 1.64 liters/h/kg and 3.56 and 2.74 liters/kg, respectively, with body weight as a significant correlate of both CL and V SS. The relative bioavailability (F) of ZDV and ddI in the triple combination compared to that in the double combination was also evaluated. No significant effects of the combination regimens on the F of ddI were detected (F TRIPLE = 1.05 andF DOUBLE = 1 by definition), but theF of ZDV was markedly reduced by the triple combination, being only 67.7% of that of the double combination. Large (>50%) intraindividual variability was associated with both ZDV and ddI pharmacokinetics. Individual cumulative area under the plasma drug level-time curve of the three drugs was calculated for the entire study period as a measure of drug exposure based on the individual data and the final-model estimates of structural and statistical parameters.

Lymphocyte phenotype does not predict immune function in pediatric patients infected with human immunodeficiency virus type 1

1989 ◽  
Vol 115 (6) ◽  
pp. 944-948 ◽  
Author(s):  
Juanita Petersen ◽  
Joseph Church ◽  
Edward Gomperts ◽  
Robertson Parkman
Keyword(s):  
Human Immunodeficiency Virus ◽  
Immune Function ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Pediatric Patients ◽  
Lymphocyte Phenotype ◽  
Immunodeficiency Virus

Causes of Death in Pediatric Patients Vertically Infected by the Human Immunodeficiency Virus Type 1 in Madrid, Spain, From 1982 to Mid-2009

2011 ◽  
Vol 30 (6) ◽  
pp. 495-500 ◽  
Author(s):  
Claudia Palladino ◽  
Francisco J. Climent ◽  
Ma Isabel De José ◽  
Santiago Jimenez De Ory ◽  
Jose María Bellón ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Causes Of Death ◽  
Pediatric Patients ◽  
Immunodeficiency Virus

scholarly journals Evaluation of Pharmacokinetics, Safety, Tolerance, and Activity of Combination of Zalcitabine and Zidovudine in Stable, Zidovudine‐Treated Pediatric Patients with Human Immunodeficiency Virus Infection

1997 ◽  
Vol 175 (5) ◽  
pp. 1039-1050 ◽  
Author(s):  
Saroj S. Bakshi ◽  
Paula Britto ◽  
Edmund Capparelli ◽  
Lynne Mofenson ◽  
Mary Glen Fowler ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Virus Infection ◽  
Human Immunodeficiency Virus Infection ◽  
Pediatric Patients ◽  
Immunodeficiency Virus

Gastrostomy Tube Insertion for Improvement of Adherence to Highly Active Antiretroviral Therapy in Pediatric Patients With Human Immunodeficiency Virus

PEDIATRICS ◽  
2000 ◽  
Vol 105 (6) ◽  
pp. e80-e80 ◽  
Author(s):  
D. Shingadia ◽  
R. M. Viani ◽  
R. Yogev ◽  
H. Binns ◽  
W. M. Dankner ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Antiretroviral Therapy ◽  
Highly Active Antiretroviral Therapy ◽  
Pediatric Patients ◽  
Gastrostomy Tube ◽  
Tube Insertion ◽  
Highly Active ◽  
Immunodeficiency Virus

Adherence to Antiretroviral Therapy in Pediatric Patients With Human Immunodeficiency Virus (HIV-1)

2010 ◽  
Vol 25 (6) ◽  
pp. 500-504 ◽  
Author(s):  
Gail Burack ◽  
Sunanda Gaur ◽  
Roseann Marone ◽  
Anna Petrova
Keyword(s):  
Human Immunodeficiency Virus ◽  
Antiretroviral Therapy ◽  
Pediatric Patients ◽  
Immunodeficiency Virus ◽  
Hiv 1
Sign in / Sign up

Export Citation Format

Share Document